37 studies found for:    belimumab
Show Display Options
Rank Status Study
1 Completed
Has Results
Study of Belimumab Administered Subcutaneously to Healthy Subjects
Condition: Healthy
Interventions: Biological: Single Dose Group: Belimumab IV 240 mg;   Biological: Single Dose Group: Belimumab SC 2 x 120 mg;   Biological: Single Dose Group: Belimumab SC 1 x 240 mg;   Biological: Single Dose Group: Belimumab SC 1 x 200 mg;   Biological: Multiple Dose Group: Belimumab SC 2 x 120 mg weekly;   Biological: Multiple Dose Group: Belimumab SC 1 x 200 mg weekly
2 Terminated Desensitization With Belimumab in Sensitized Patients Awaiting Kidney Transplant
Condition: Desensitization Before Kidney Transplant
Intervention: Drug: Belimumab
3 Terminated
Has Results
Phase 2 Study of Belimumab Administered Subcutaneously to Subjects With Systemic Lupus Erythematosus (SLE)
Condition: Systemic Lupus Erythematosus
Intervention: Drug: Belimumab 100 mg SC
4 Active, not recruiting A Continuation Trial for Subjects With Lupus Who Completed Protocol HGS1006-C1056 in the United States
Condition: Systemic Lupus Erythematosus
Interventions: Biological: Belimumab 1 mg/kg;   Biological: Belimumab 10 mg/kg
5 Completed
Has Results
A Study of Belimumab in Subjects With Systemic Lupus Erythematosus
Condition: Systemic Lupus Erythematosus
Interventions: Drug: Placebo;   Drug: Belimumab 1 mg/kg;   Drug: Belimumab 10 mg/kg
6 Completed
Has Results
A Study of Belimumab in Subjects With Systemic Lupus Erythematosus (SLE)
Condition: Systemic Lupus Erythematosus
Interventions: Drug: Placebo;   Drug: Belimumab 1 mg/kg;   Drug: Belimumab 10 mg/kg
7 Recruiting A Study to Evaluate the Effect of Belimumab on Vaccine Responses in Subjects With Systemic Lupus Erythematosus (SLE)
Condition: Systemic Lupus Erythematosus
Interventions: Biological: Belimumab plus Early Vaccination;   Biological: Belimumab plus Late Vaccination
8 Unknown  A Study of Belimumab in Treating Symptomatic Waldenstroms Macroglobulinaemia
Condition: Symptomatic Waldenstroms Macroglobulinaemia
Intervention: Drug: Belimumab
9 Recruiting Belimumab (BENLYSTA®) Pregnancy Registry
Condition: Systemic Lupus Erythematosus
Intervention: Drug: belimumab
10 Completed Phase 1 Study of Belimumab in Subjects With Systemic Lupus Erythematosus (SLE)
Condition: Systemic Lupus Erythematosus
Interventions: Biological: belimumab;   Biological: Placebo
11 Recruiting A Study of Belimumab in the Prevention of Kidney Transplant Rejection
Condition: Transplantation, Organ
Interventions: Drug: Belimumab (10mg/kg) will be given as an intravenous solution over a 1 hour time period week 0, week 2, week 4, week 8, week 12, week 16 and week 20.;   Drug: Placebo (to match belimumab) will be given as an intravenous solution over a 1 hour time period at week 0, week 2, week 4, week 8, week 12, week 16 and week 20.
12 Recruiting Safety and Effectiveness of Belimumab in Systemic Lupus Erythematosus Registry
Condition: Systemic Lupus Erythematosus
Interventions: Biological: BENLYSTA;   Other: SLE treatment
13 Recruiting A Study of Belimumab in Idiopathic Membranous Glomerulonephropathy
Condition: Glomerulonephritis, Membranous
Intervention: Drug: belimumab
14 Completed
Has Results
Safety and Efficacy Study of LymphoStat-B (Belimumab) in Subjects With Systemic Lupus Erythematosus (SLE)
Condition: Lupus Erythematosus, Systemic
Interventions: Drug: Placebo;   Drug: Belimumab 1 mg/kg;   Drug: Belimumab 4 mg/kg;   Drug: Belimumab 10 mg/kg
15 Recruiting Belimumab Assessment of Safety in SLE
Condition: Systemic Lupus Erythematosus
Interventions: Biological: Placebo plus standard therapy;   Biological: Belimumab 10 mg/kg plus standard therapy;   Other: Standard therapy
16 Completed Efficacy and Safety of Belimumab in Subjects With Primary Sjögren's Syndrome
Condition: Sjögren's Syndrome
Intervention: Drug: Belimumab
17 Recruiting Belimumab in Remission of VASculitis
Condition: Vasculitis
Interventions: Biological: Placebo;   Biological: Belimumab 10 mg/kg;   Drug: Azathioprine
18 Recruiting Efficacy and Safety of Belimumab in Patients With Active Lupus Nephritis
Condition: Lupus Nephritis
Interventions: Biological: Placebo plus standard therapy;   Biological: Belimumab 10 mg/kg plus standard therapy;   Drug: Standard therapy
19 Active, not recruiting A Study of Belimumab Administered Subcutaneously in Subjects With Systemic Lupus Erythematosus (SLE)
Condition: Systemic Lupus Erythematosus
Interventions: Biological: Placebo plus standard therapy;   Biological: Belimumab 200 mg SC plus standard therapy;   Drug: Standard therapy
20 Withdrawn Efficacy and Safety Study of Intravenous Belimumab Versus Placebo in Subjects With Idiopathic Membranous Nephropathy
Condition: Glomerulonephritis, Membranous
Interventions: Drug: Belimumab 10 mg;   Drug: Placebo

Previous Page Studies Shown (1-20) Next Page (21-37) Show next page of results
Indicates status has not been verified in more than two years